Kyverna Therapeutics, Inc. (KYTX) Financial Statements
Free cash flow over the same period: -$160.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KYTXKyverna Therapeutics, Inc.Follow KYTX — free
—
Price chart with a free account
- Market cap
- 333.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Research & development | 112.5 | 133.7 | 115.3 | |
| Operating income | -142.6 | -169.8 | -158.9 | |
| Pre-tax income | -127.5 | -161.3 | -152.6 | |
| Income tax | 0.0 | 0.0 | — | |
| Net income | -127.5 | -161.3 | -152.6 | |
| Diluted EPS ($) | -3.33 | -3.64 | -2.51 | |
| Diluted shares (mn) | 38.3 | 44.3 | — |
USD millions · SEC XBRL
Kyverna Therapeutics, Inc. — questions
- What is Kyverna Therapeutics, Inc.'s net income?
- -$152.6M over the twelve months to 2026-06-30.
- What is Kyverna Therapeutics, Inc.'s free cash flow?
- -$160.2M over the twelve months to 2026-06-30.
- What are Kyverna Therapeutics, Inc.'s diluted earnings per share?
- $-2.51 over the twelve months to 2026-06-30.
Every figure on this page comes from Kyverna Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.